G15 Inhibitor

Powder

98.00%

Powder: -20°C for 3 years
In solvent: -80°C for 2 years

370.24

C19H16BrNO2

1161002-05-6

[H][C@]12CC=C[C@@]1([H])c1ccccc1N[C@H]2c1cc2OCOc2cc1Br

GPER: 20nM (Ki)

DMSO: 41.67mg/mL (112.55mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Estrogen Receptor/ERR

G-15 antagonizes the anti-depressive effects of estrogen in vivo[1].

G15 and G1 were first dissolved in DMSO and diluted with saline; the final concentration in DMSO was 1 mM. Desipramine and E2 (cyclodextrin-encapsulated, 4-5.5% E2) were dissolved in saline solution and DMSO was added to a final concentration of 1 mM. An appropriate vehicle-treated group (saline with 1 mM DMSO) was included as a control (sham). All solutions were freshly prepared before each experimental series. Independent groups of mice (n=12-16) were treated with two consecutive intraperitoneal injections as follows: vehicle solution + vehicle solution (sham group); vehicle + G-1 (indicated amount in nmol); vehicle + desipramine (10mg/kg); G15 (10nmol/mouse) + desipramine (10mg/kg); G15 (10nmol/mouse) + G-1 (1nmol/mouse); vehicle + G15 (10nmol/mouse); vehicle + soluble E2 (5 mg/kg); G15 (25nmol/mouse) + soluble E2 (5 mg/kg). The second compound was injected 15 min (7 min for E2) after the first injection and the tail suspension test performed 30 min after the second injection[1].

1mg
1 mM: 2.7009
5 mM: 0.5402
10 mM: 0.2701
50 mM: 0.054

5mg
1 mM: 13.5044
5 mM: 2.7009
10 mM: 1.3504
50 mM: 0.2701

10mg
1 mM: 27.0088
5 mM: 5.4018
10 mM: 2.7009
50 mM: 0.5402

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Home; Others